Medical devices, healthcare technology and the business of care
PMA approval · P170012

HEMOBLAST Bellows

Dilon Technologies, Inc. · Decision date Dec 15, 2017

MEDTECHLEDGER EXPLANATIONP170012

What did the FDA approve?

The FDA database entry records approval of HEMOBLAST Bellows under PMA number P170012, with a decision date of December 15, 2017. The applicant is Dilon Technologies, Inc., and the device is classified as an absorbable collagen hemostatic agent with thrombin under product code PMX.

The stated indication is use in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical. The statement explicitly excludes neurosurgical, ophthalmic, and urological procedures. The source does not provide supplement type, supplement reason, or clinical data supporting the approval.

FDA approval order statement

Approval of the Hemoblast Bellows. This device is indicated for surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Dec 15, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170012
Regulatory pathway
Premarket approval application
Product code
PMX
Decision code
APPR
Decision date
Dec 15, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Absorbable collagen hemostatic agent with thrombin.

Product code
PMX
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170012 received

    Application receipt date recorded by FDA.

  2. P170012 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P170012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170012

Product / regulatory recordCompanyPathwayDecision dateSource
HEMOBLAST BellowsP170012/S032
Dilon Technologies, Inc.PMA supplementSep 3, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Dilon Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
12050 Jefferson Ave., Suite 340, Newport News, VA, 23606

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records